The therapeutic use of hematopoietic growth factors

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 1, 1998, Pages 1-6

  Costa, John J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; DRUG ISOLATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; MAST CELL; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; STEM CELL; TARGET CELL;

EID: 0031938341     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70185-X     Document Type: Article

References (22)

1. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
2. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-5.
3. Waller CF, Bertz H, Wenger MK, Fetscher S, Hardung M, Engelhardt M, et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996;18:279-83.
4. Bociek RG, Armitage JO. Hematopoietic growth factors. CA Cancer J Clin 1996;46:165-84.
5. Glaspy J, Davis MW, Parker WRL, Foote MA, McNiece I. Biology and clinical potential of stem-cell factor. Cancer Chemother Pharmacol 1996;38(suppl):S53-7.
6. Fraser JK, Lill MCC, Figlin RA. The biology of the cytokine sequence cascade. Semin Oncol 1996;23(suppl 4):2-8.
7. Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990;50:606-14.
8. Denzlinger C, Tetzloff W, Gerhartz HH, Pokorny R, Sagebiel S, Haberl C, et al. Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers. Blood 1993;81:2007-13.
9. Hoglund M, Bengtsson M, Cour-Chabernaud V, Dabouz-Harrouche F, Simonsson B, Smedmyr B, et al. Glycosylated rHuG-CSF is more potent than non-glycosylated rHuG-CSF in mobilization of peripheral blood progenitor cells (PBPC) in healthy volunteers, [abstract]. Blood 1995;86(suppl 1):1842.
10. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
11. Lifton R, Bennett JM. Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Hematol Oncol Clin North Am 1996;10:825-39.
12. Glaspy J. Clinical applications of stem cell factor. Curr Opin Hematol 1996;3:223-9.
13. Costa JJ, Galli SJ. Mast cells and basophils. In: Rich R, editor. Principles and practice of clinical Immunology. St. Louis: Mosby;1996. p. 408-30.
14. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996;183:2681-6.
15. Ganser A, Karthaus M. Clinical use of hematopoietic growth factors. Curr Opinion Oncol 1996;8:265-9.
16. Croockewit AJ, Koopmans PP, de Pauw BE. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Clin Pharmacol Ther 1996;59:l-6.
17. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NO. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996;88:3323-8.
18. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a Phase I/II trial. Blood 1997;89:3136-47.
19. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, et al. A randomized Phase 3 study of PBPC mobilization by stem cell factor (SCF, Stemgen) and filgrastim in patients with high-risk breast cancer [abstract]. Blood 1997. In press.
20. Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis [letter]. N Engl J Med 1991;325:587.
21. Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, et al. Development of autoantibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990;335:434-7.
22. Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997;350:855-9.